Form 4: ARCH Venture Partners Boosts Neumora Stake via Pre-Planned Purchase

ARCH Venture Partners X, LLC and affiliated funds reported a pre-planned acquisition of 1,915,700 shares of Neumora Therapeutics, Inc. common stock by ARCH Venture Fund XII, L.P. at $2.61 per share, effective October 27, 2025.

Summary

• ARCH Venture Partners X, LLC, along with several affiliated funds and managing directors, filed a Form 4 for Neumora Therapeutics, Inc. (NMRA).
• The filing reports a pre-planned acquisition of 1,915,700 shares of Common Stock by ARCH Venture Fund XII, L.P.
• The transaction date for this acquisition is October 27, 2025, with a purchase price of $2.61 per share.
• Following this transaction, the total beneficial ownership across all reported ARCH Venture entities is 33,847,838 shares of Neumora Therapeutics, Inc. common stock.
• ARCH Venture Partners X, LLC and its affiliates are identified as both a Director and a 10% Owner of Neumora Therapeutics, Inc.

Sentiment

Score: 8

Explanation: The acquisition by a significant institutional investor and 10% owner, especially a pre-planned purchase, indicates strong confidence in the company's future prospects.

Positives

• A significant institutional investor and 10% owner, ARCH Venture Partners, is increasing its stake in Neumora Therapeutics, Inc., signaling confidence.
• The acquisition of 1,915,700 shares by ARCH Venture Fund XII, L.P. at $2.61 per share represents a substantial investment.
• The total beneficial ownership of 33,847,838 shares by the ARCH Venture group underscores their long-term commitment to the company.

Risks

• The transaction date of October 27, 2025, is in the future, indicating a pre-planned purchase under Rule 10b5-1(c), which means the actual execution is yet to occur and is subject to market conditions at that future date.

Future Outlook

The pre-planned nature of the transaction suggests a long-term strategic investment by ARCH Venture Partners in Neumora Therapeutics, Inc.

Industry Context

Venture capital firms like ARCH Venture Partners often take significant stakes in biotech companies like Neumora Therapeutics, Inc., providing capital and strategic guidance. Increased investment by such a firm can be seen as a vote of confidence in the company's pipeline and future prospects within the competitive biotech landscape.

Related Party Transactions

• The acquisition of shares by ARCH Venture Fund XII, L.P., an affiliate of ARCH Venture Partners X, LLC, which is a Director and 10% Owner of Neumora Therapeutics, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the increased stake by a major institutional investor as a positive signal, potentially boosting investor confidence and share price.
• Management may see this as reinforced confidence from a key investor and board member, potentially aligning interests further.

Next Steps

• The actual execution of the pre-planned share purchase is scheduled for October 27, 2025.

Key Dates

Recommendation

The significant purchase of shares by a major institutional investor and 10% owner, ARCH Venture Partners, signals strong conviction in Neumora Therapeutics, Inc.'s value and future potential. Such insider buying, especially when pre-planned, often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Neumora Therapeutics, NMRA, ARCH Venture Partners, insider buying, Form 4, beneficial ownership, institutional investment, biotech, venture capital, stock purchase, 10b5-1 plan